PIRS News and Press, Pieris Pharmaceuticals Inc. From 08/10/20

Pieris Pharmaceuticals, Inc. (PIRS) Q2 2020 Earnings Conference Call August 10, 2020 08:00 AM ET Company Participants Tom Bures - Vice President of Finance Steve Yoder - President and Chief Executive Officer Ingmar Bruns - Senior Vice President and Head of Clinical Development ...

Company to Host an Investor Conference Call on Monday, August 10, 2020 at 8:00 AM EDT PRS-060/AZD1402 phase 2a trial in asthma to start in fourth quarter Signed clinical trial collaboration agreement with Lilly for supply of ramucirumab for phase 2 trial of PRS-343 PRS-343 ph...

Pieris Pharmaceuticals (NASDAQ: PIRS )  has entered into a clinical trial collaboration and supply agreement with Eli Lilly (NYSE: LLY ) to evaluate the safety and efficacy of combining Pieris' PRS-343, a 4-1BB/HER2 bispecific for HER2-positive tumors, with Lilly's ramucirumab, a V...

BOSTON, MA / ACCESSWIRE / August 10, 2020 / Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS) , a clinical-stage biotechnology company advancing novel biotherapeutics through its proprietary Anticalin ® technology platform for respiratory diseases, cancer, and other indications, toda...

BOSTON, MA / ACCESSWIRE / August 3, 2020 / Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS) , a clinical-stage biotechnology company advancing novel biotherapeutics through its proprietary Anticalin® technology platform for respiratory diseases, cancer and other indications, today announced ...

BOSTON, MA / ACCESSWIRE / July 23, 2020 / Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS) , a clinical-stage biotechnology company advancing novel biotherapeutics through its proprietary Anticalin ® technology platform for respiratory diseases, cancer, and other indications, today announce...

The FDA has instituted a partial clinical hold on Phase 1 clinical trials of Pieris Pharmaceuticals' (NASDAQ: PIRS ) lead candidate PRS-343 until the company conducts an additional in-use and compatibility study with various infusion materials under specific conditions aimed at confirmin...

FDA requested a confirmatory laboratory-based in-use and compatibility study before enrolling new patients Currently-enrolled patients may continue to receive PRS-343 In its telephonic communication, FDA did not cite any adverse events in connection with its request Company ...

BOSTON, MA / ACCESSWIRE / June 8, 2020 / Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS), a clinical-stage biotechnology company advancing novel biotherapeutics through its proprietary Anticalin® technology platform for respiratory, cancer, and other diseases, announced today that due to t...

BOSTON, MA / ACCESSWIRE / May 28, 2020 / Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS) , a clinical-stage biotechnology company advancing novel biotherapeutics through its proprietary Anticalin ® technology platform for respiratory diseases, cancer, and other indications, announc...